PRCT vs. NARI, IART, ICUI, TNDM, ATEC, IRTC, AXNX, ATRC, LMAT, and NVCR
Should you be buying PROCEPT BioRobotics stock or one of its competitors? The main competitors of PROCEPT BioRobotics include Inari Medical (NARI), Integra LifeSciences (IART), ICU Medical (ICUI), Tandem Diabetes Care (TNDM), Alphatec (ATEC), iRhythm Technologies (IRTC), Axonics (AXNX), AtriCure (ATRC), LeMaitre Vascular (LMAT), and NovoCure (NVCR). These companies are all part of the "surgical & medical instruments" industry.
Inari Medical (NASDAQ:NARI) and PROCEPT BioRobotics (NASDAQ:PRCT) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership.
91.0% of Inari Medical shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 10.6% of Inari Medical shares are owned by insiders. Comparatively, 19.6% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Inari Medical has a net margin of -0.33% compared to Inari Medical's net margin of -77.75%. PROCEPT BioRobotics' return on equity of 1.23% beat Inari Medical's return on equity.
Inari Medical received 29 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. Likewise, 67.50% of users gave Inari Medical an outperform vote while only 59.52% of users gave PROCEPT BioRobotics an outperform vote.
Inari Medical has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.
Inari Medical currently has a consensus price target of $73.71, suggesting a potential upside of 53.64%. PROCEPT BioRobotics has a consensus price target of $45.60, suggesting a potential downside of 7.73%. Given PROCEPT BioRobotics' higher possible upside, analysts plainly believe Inari Medical is more favorable than PROCEPT BioRobotics.
Inari Medical has higher revenue and earnings than PROCEPT BioRobotics. Inari Medical is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Inari Medical had 11 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 12 mentions for Inari Medical and 1 mentions for PROCEPT BioRobotics. Inari Medical's average media sentiment score of 1.62 beat PROCEPT BioRobotics' score of 0.20 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.
Summary
Inari Medical beats PROCEPT BioRobotics on 11 of the 18 factors compared between the two stocks.
Get PROCEPT BioRobotics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
PROCEPT BioRobotics Competitors List
Related Companies and Tools